Physician profile
Nirmal Jacob
NPI 1902435092
$2,193.36
in general payments reported to CMS, 2019-2025
19 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.84 · 2022: $462 · 2023: $850 · 2024: $642 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.22 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $591.78 | 2022-2024 | Briviact, Fintepla, Rystiggo |
| Jazz Pharmaceuticals INC. | $565.48 | 2022-2025 | Epidiolex |
| E.R. Squibb & Sons, L.L.C. | $190.90 | 2022-2023 | Zeposia |
| Abbvie INC. | $181.59 | 2022-2025 | |
| Aquestive Therapeutics, INC. | $102.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.17 | 2023 | |
| Celgene Corporation | $80.19 | 2023-2024 | Zeposia |
| Neurelis, INC. | $77.50 | 2022 | |
| Allergan, INC. | $47.10 | 2022 | |
| Sk Life Science, INC. | $44.99 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $36.77 | 2024 | Motpoly Xr |
| Genentech USA, INC. | $32.56 | 2023 | Ocrevus, Enspryng |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2024 | Dojolvi |
| Biogen, INC. | $29.60 | 2024 | Tysabri |
| Astrazeneca Pharmaceuticals LP | $20.84 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.94 | 2024 | |
| Argenx US, INC. | $16.29 | 2023 | Vyvgart |
| Collegium Pharmaceutical, INC. | $15.65 | 2024 | Belbuca |
| Alexion Pharmaceuticals, INC. | $15.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmal Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.